NO20083031L - Tiadiazolderivater som anti-diabetiske agenter - Google Patents

Tiadiazolderivater som anti-diabetiske agenter

Info

Publication number
NO20083031L
NO20083031L NO20083031A NO20083031A NO20083031L NO 20083031 L NO20083031 L NO 20083031L NO 20083031 A NO20083031 A NO 20083031A NO 20083031 A NO20083031 A NO 20083031A NO 20083031 L NO20083031 L NO 20083031L
Authority
NO
Norway
Prior art keywords
compounds
inhibitors
prevention
formula
treatment
Prior art date
Application number
NO20083031A
Other languages
English (en)
Norwegian (no)
Inventor
Gary Mark Coppola
Thalaththani Ralalage Vedananda
James Richard Wareing
Travis Mathew Stams
Sidney Wolf Topiol
Gregory Raymond Bebernitz
David Barnes
Katsumasa Nakajima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083031(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20083031L publication Critical patent/NO20083031L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20083031A 2005-12-08 2008-07-04 Tiadiazolderivater som anti-diabetiske agenter NO20083031L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74857305P 2005-12-08 2005-12-08
PCT/US2006/046545 WO2007067615A2 (en) 2005-12-08 2006-12-06 Thiadiazole derivatives as antidiabetic agents

Publications (1)

Publication Number Publication Date
NO20083031L true NO20083031L (no) 2008-08-28

Family

ID=37950917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083031A NO20083031L (no) 2005-12-08 2008-07-04 Tiadiazolderivater som anti-diabetiske agenter

Country Status (26)

Country Link
US (1) US7700633B2 (es)
EP (1) EP1963292B1 (es)
JP (1) JP2009519248A (es)
KR (1) KR20080074969A (es)
CN (1) CN101326173A (es)
AR (1) AR056838A1 (es)
AT (1) ATE546440T1 (es)
AU (1) AU2006321905B2 (es)
BR (1) BRPI0619600A2 (es)
CA (1) CA2629857A1 (es)
CR (1) CR10049A (es)
EC (1) ECSP088506A (es)
ES (1) ES2381280T3 (es)
IL (1) IL191549A0 (es)
MA (1) MA30202B1 (es)
NO (1) NO20083031L (es)
NZ (1) NZ568243A (es)
PE (2) PE20100733A1 (es)
PL (1) PL1963292T3 (es)
PT (1) PT1963292E (es)
RU (1) RU2008127254A (es)
TN (1) TNSN08249A1 (es)
TW (1) TW200732315A (es)
UA (1) UA94724C2 (es)
WO (1) WO2007067615A2 (es)
ZA (1) ZA200804074B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397177T3 (es) * 2005-12-08 2013-03-05 Novartis Ag Derivados de 1,2,5-tiazolidina útiles para el tratamiento de condiciones mediadas por proteínas tirosina fosfatasas (PTPASA)
BRPI0619547A2 (pt) * 2005-12-08 2011-10-04 Novartis Ag 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
CN113365992B (zh) * 2018-12-21 2024-05-28 晶体制药独资有限公司 用于沃塞洛托的制备的方法和中间体
MX2021010544A (es) * 2019-03-14 2021-10-01 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
JP2023508914A (ja) * 2019-12-20 2023-03-06 カリコ ライフ サイエンシーズ エルエルシー プロテインチロシンホスファターゼ分解剤及びその使用方法
CA3211545A1 (en) * 2021-03-11 2022-09-15 Liansheng Li Heterocycles and uses thereof
AU2022387106A1 (en) * 2021-11-11 2024-05-23 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150523A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150535A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646508A (zh) * 2002-04-03 2005-07-27 诺瓦提斯公司 作为ptp酶1b抑制剂的5－取代的1,1－二氧代－1,2,5－噻二唑烷－3－酮衍生物
GB0225986D0 (en) 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
EP1594497B1 (en) * 2002-12-30 2009-05-27 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
BRPI0619547A2 (pt) * 2005-12-08 2011-10-04 Novartis Ag 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
ES2397177T3 (es) * 2005-12-08 2013-03-05 Novartis Ag Derivados de 1,2,5-tiazolidina útiles para el tratamiento de condiciones mediadas por proteínas tirosina fosfatasas (PTPASA)
US8084448B2 (en) * 2006-03-31 2011-12-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MA30202B1 (fr) 2009-02-02
PL1963292T3 (pl) 2012-07-31
ZA200804074B (en) 2009-03-25
TNSN08249A1 (en) 2009-10-30
AR056838A1 (es) 2007-10-24
ES2381280T3 (es) 2012-05-24
JP2009519248A (ja) 2009-05-14
PE20100733A1 (es) 2010-10-29
BRPI0619600A2 (pt) 2011-10-11
IL191549A0 (en) 2008-12-29
ECSP088506A (es) 2008-07-30
US7700633B2 (en) 2010-04-20
KR20080074969A (ko) 2008-08-13
PT1963292E (pt) 2012-05-10
NZ568243A (en) 2011-07-29
WO2007067615A3 (en) 2007-11-15
CA2629857A1 (en) 2007-06-14
EP1963292A2 (en) 2008-09-03
PE20071031A1 (es) 2007-11-15
AU2006321905A1 (en) 2007-06-14
CN101326173A (zh) 2008-12-17
ATE546440T1 (de) 2012-03-15
AU2006321905B2 (en) 2011-08-11
RU2008127254A (ru) 2010-01-20
CR10049A (es) 2008-08-25
US20080262050A1 (en) 2008-10-23
TW200732315A (en) 2007-09-01
EP1963292B1 (en) 2012-02-22
WO2007067615A2 (en) 2007-06-14
UA94724C2 (en) 2011-06-10

Similar Documents

Publication Publication Date Title
NO20083031L (no) Tiadiazolderivater som anti-diabetiske agenter
NO20083030L (no) 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
NO20044745L (no) 5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
Wakino et al. Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
Rotili et al. Identification of tri‐and tetracyclic pyrimidinediones as sirtuin inhibitors
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NO20070506L (no) Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
TN2011000201A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase - iv inhibitors for the treatment or prevention of diabetes
WO2010074588A3 (en) Pharmaceutical compounds
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
WO2010001169A3 (en) Chemical compounds 251
BRPI0508144A (pt) derivados de oligossacarìdeos sulfatados composto da fórmula geral; composição farmacêutica ou veterinária seu uso; método para a prevenção ou tratamento pelo uso da mesma
WO2007149451A3 (en) Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
NO20084396L (no) Kombinasjonsterapi
BRPI0518013A (pt) inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos
WO2007136640A3 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2006130613A3 (en) Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
WO2008046082A3 (en) Use of heterocyclic compounds as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application